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Summary
 
Mast cells have long been believed to be the central effector cells in the development of immu-
noglobulin (Ig)E-dependent anaphylaxis. In this study, we investigated the role of mast cells in
IgE-dependent hapten-induced active fatal anaphylaxis using mast cell–deficient WBB6F1-
 
W/W
 
v
 
 (
 
W/W
 
v
 
) and congenic normal (
 
1
 
/
 
1
 
) mice. Although a 5-min delay in shock signs and
death were observed in 
 
W/W
 
v
 
 
 
mice, 100% fatal reactions to penicillin V (Pen V) occurred in
both 
 
1
 
/
 
1
 
 and 
 
W/W
 
v
 
 mice. Administration of monoclonal anti–IL-4 antibody completely
prevented the fatal reactions, and the effect of anti–IL-4 was associated with its suppressive ac-
tivity on Pen V–specific serum levels of IgE, but not IgG. The platelet-activating factor (PAF)
antagonist, BN 50739, completely prevented the fatal reactions in both strains of mice. Our ki-
netic study revealed, in contrast to no elevation of plasma histamine level in 
 
W/W
 
v
 
 mice, high
levels of PAF in the circulation after challenge in both 
 
1
 
/
 
1
 
 and 
 
W/W
 
v
 
 mice, albeit to a lesser
degree in the latter case. These data indicate that cells other than mast cells are sufficient to in-
duce an IgE-dependent active fatal anaphylaxis by elaborating PAF, which is the critical medi-
ator for fatal murine anaphylaxis.
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W/W
 
v
 
 mice • immunoglobulin E • platelet-activating factor •
penicillin V
 
M
 
ast cells express receptors on their cell surface that
bind IgE Abs with high specificity and affinity
(Fc
 
e
 
RI [1–3]). Antigen-mediated cross-linkage of the Fc
 
e
 
RI
triggers mast cells to release a wide spectrum of mediators
critical for the development of immediate hypersensitivity
reactions, including anaphylaxis.
Understanding the role of mast cells in anaphylaxis has
been aided by the availability of mast cell–deficient 
 
W/W
 
v
 
and 
 
SI/SI
 
d
 
 
 
mice. Several groups of investigators have estab-
lished that 
 
W/W
 
v
 
 and 
 
SI/SI
 
d
 
 mice that are actively sensi-
tized to protein antigens such as OVA or chicken gamma-
globulin (CGG),
 
1
 
 can exhibit active fatal anaphylaxis (4–8).
Thus, mast cells may not contribute importantly to pro-
tein-induced anaphylaxis. Some evidence indicates that
protein-induced anaphylaxis can be elicited by IgG Abs (9,
10) even in the absence of IgE Abs (11), suggesting that
cells other than mast cells that bind IgG Abs elaborate suffi-
cient mediators leading to fatal reactions. Nevertheless,
mast cells have long been believed to be the central effector
cells in the development of IgE-dependent anaphylaxis.
However, the in vivo extent to which the reactions are
mast cell–dependent remains to be elucidated due to the
lack of a suitable animal model of IgE-dependent anaphy-
laxis.
We have recently developed a murine model of IgE-
dependent, penicillin V (Pen V)–induced active fatal ana-
phylaxis (12). The reaction was 100% fatal in C57BL/6
mice and was exclusively IgE dependent, since (
 
a
 
) IgE, but
not IgG, Abs against Pen V passively sensitized normal
mice to develop severe anaphylactic reactions; (
 
b
 
) anti–IL-4
mAb completely prevented the fatal reaction; and (
 
c
 
) the
effect of anti–IL-4 was associated with its suppressive activ-
ity on Pen V–specific serum IgE, but not IgG, levels. This
model allowed us to investigate the role of mast cells in
IgE-dependent anaphylaxis. In this study, the role of mast
cells in IgE-dependent Pen V–induced anaphylaxis using
genetically mast cell–deficient WBB6F1-
 
W/W
 
v
 
 
 
(
 
W/W
 
v
 
)
and congenic normal (
 
1
 
/
 
1
 
) mice was investigated. It was
 
1
 
Abbreviations used in this paper:
 
 CGG, chicken gammaglobulin; NP, nitro-
phenol; PAF, platelet-activating factor; PCA, passive cutaneous anaphy-
laxis; Pen V, penicillin V.
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found that virtually identical Pen V–induced fatal anaphy-
laxis occurred in mast cell–deficient mice, indicating that
mast cells are not essential for the development of IgE-
dependent anaphylaxis.
 
Materials and Methods
 
Animals.
 
Female mast cell–deficient WBB6F1-
 
W/W
 
v
 
 (
 
W/
W
 
v
 
) and mast cell–sufficient control WBB6F1 
 
1
 
/
 
1
 
 mice were
purchased from The Jackson Laboratory (Bar Harbor, ME), and
were kept in our animal facility for at least 2 wk before use. All
mice were used at 8–9 wk of age.
 
Reagents.
 
Pen V, OVA (grade V), and BSA (fraction V) were
purchased from Sigma Chemical Co. (St. Louis, MO). Platelet-
activating factor (PAF) antagonist, BN 50739, was provided by
Dr. P. Braquet (Institut Henri Beaufour, Le Plessis-Robinson,
France). 
 
Bordetella pertussis 
 
was obtained from the National Insti-
tute of Health (Seoul, Korea).
 
Abs.
 
The rat–mouse hybridoma, 11B11, which secretes rat
IgG1 specific for murine IL-4 (13), was purchased from American
Type Culture Collection (Rockville, MD). As a control mAb,
J4-1 (14), which secretes rat IgG1 with specificity for the hapten,
nitrophenol (NP), was provided by Dr. F.D. Finkelman, Uni-
formed Services University of the Health Sciences (Bethesda,
MD). Both mAbs were prepared as ascites in pristane-primed
nude mice. Preparations were precipitated in 45% ammonium
sulfate and dialyzed against PBS (pH 7.2), and protein was quanti-
tated before use. The IgG1 mAb specific for Pen V (12) was used
to measure Pen V–specific serum IgG1 levels (see below).
 
Pen V–Protein Conjugates.
 
Conjugates (Pen V–OVA and Pen
V–BSA) were prepared as described previously (12). In brief, 20
mg of OVA or BSA in 5 ml of 50 mM veronal buffer (pH 8.5)
was added to 100 mg of Pen V in 5 ml veronal buffer and stirred
overnight at 37
 
8
 
C. The pH was maintained between 8.5 and 9.0
by adding 1 N NaOH. The reaction mixture was centrifuged,
and the supernatant was dialyzed for 7 d against 0.01 M PBS (pH
7.2). Aliquots of the dialyzed supernatant (5 mg/ml) were stored
at 
 
2
 
20
 
8
 
C.
 
Induction of Active Systemic Anaphylaxis to Pen V.
 
Mice were
sensitized by intraperitoneal injection of 500 
 
m
 
g of Pen V–OVA
conjugate plus 2 
 
3 
 
10
 
9
 
 
 
B
 
.
 
 pertussis 
 
and 1.0 mg of alum. Challenge
was given as an injection of 100 
 
m
 
g i.v. of Pen V–BSA conjugate
14 d later (12).
 
Measurement of Pen V–specific Serum Levels of IgE and IgG1.
 
Pen V–specific serum IgE levels were determined by a passive cu-
taneous anaphylaxis (PCA) reaction as described previously (12).
In brief, serial dilutions of individual sera from mice immunized
with Pen V–OVA were injected intracutaneously into the shaved
backs of male Wistar rats. After 24 h, 1 ml of 1% Evan’s blue dye
in PBS containing 4 mg of Pen V–BSA was injected intrave-
nously. The rats were killed 30 min later, skins were removed,
and a blue spot with a diameter 
 
.
 
5 mm was regarded as a posi-
tive reaction. Pen V–specific serum IgG1 levels were determined
by an ELISA as described previously (12). Microtiter plates
(Irvine Scientific, Santa Ana, CA) were coated with 50 
 
m
 
l of Pen
V–BSA (10 
 
m
 
g/ml) in 50 mM sodium carbonate buffer, pH 9.6,
overnight at 4
 
8
 
C. After the plates were washed, a serial dilution of
sera and Pen V–specific IgG1 mAb in 2.7% gelatin was added and
incubated at 37
 
8
 
C for 1 h. After washing, peroxidase-conjugated
rabbit anti–mouse IgG1 (1:4,000; Organon-Teknika Capell,
Durham, NC) was added and incubated at 37
 
8
 
C for 45 min. After
a final washing, 75 
 
m
 
l of 
 
O
 
-phenylenediamine in phosphate-
citrate buffer (pH 5.0) was added, and color was developed. Ab-
sorbance was measured at 492 nm, and results were expressed as
concentrations, from a standard curve of known concentrations
of Pen V–specific IgG1 mAb.
 
Determination of Plasma PAF and Histamine.
 
The postchallenge
blood was taken from the heart, which had been cut open, and
was mixed with a 0.1 vol of 3.8% ice-chilled citrate solution, then
centrifuged immediately using an Eppendorf microfuge. The
plasma was stored at 
 
2
 
20
 
8
 
C until use. Plasma PAF was measured
using the method described by Sugatani et al. (15). In brief, 20–
50 
 
m
 
l of plasma was vortexed with 4 vol of 2-propanol and cen-
trifuged. Extraction of lipids from the samples was repeated three
times with 2-propanol. The supernatants were applied to a re-
verse phase, 100-mg octadecyl column (Amprep minicolumn;
Nycomed Amersham plc, Little Chalfont, Bucks, UK). The col-
umn was washed with 2 ml of 30% 2-propanol solution, followed
by 2 ml of 55% ethanol solution, and PAF was eluted with 2 ml
of 67% ethanol solution. The eluates were evaporated under ni-
trogen and separated by thin-layer chromatography on silica gel
G plates (250 
 
m
 
m, 4 
 
3 
 
20 cm, Uniplate; Analtech, Inc., Newark,
DE) with a solvent system of CHCl
 
3
 
/CH
 
3
 
OH/H
 
2
 
O (65:35:6,
vol/vol/vol). The PAF, which was located on the thin layer plate
between the areas corresponding to sphingomyelin and lysophos-
phatidylcholine, was detected by UV fluorescence after spraying
the plate with 1 mM 6-
 
p
 
-toluidine-2-naphthalenesulfonic acid.
The PAF fraction was then scraped off and extracted by the
method of Bligh and Dyer (16). The extract was evaporated un-
der nitrogen, and PAF was quantified using a SPRIA kit (Ny-
comed Amersham plc) according to the manufacturer’s protocol.
Results were expressed as concentrations, from a standard curve
of known concentrations of PAF. Plasma histamine level was as-
sayed by the method of Harvima et al. (17). 10 
 
m
 
l of plasma was
mixed with 1.5 
 
m
 
l of 
 
S
 
-adenosyl (methyl-
 
14
 
C) methionine, 40 
 
m
 
l
of 300 mM Tris-glycine buffer (pH 8.3), and 5 
 
m
 
l of histamine
 
N
 
-methyl transferase, and incubated for 90 min at 37
 
8
 
C. The re-
action was stopped by adding 20 
 
m
 
l of 10 N NaOH. The mixture
was extracted with 1 ml of toluene-isoamyl alcohol. The radioac-
tivity of the supernatant was measured using a beta counter. Re-
sults were expressed as concentrations, from a standard curve of
known concentrations of histamine.
 
Results
 
Occurrence of Pen V–induced Fatal Anaphylaxis in W/W
 
v
 
Mice.
 
As shown in Table 1, 100% (9/9) of mast cell–suffi-
cient 
 
1
 
/
 
1
 
 mice died of shock 15–20 min after the chal-
lenge injections. Typical protein-induced murine anaphy-
laxis symptoms (5, 6), including itching, increased activity,
 
Table 1.
 
Occurrence of Pen V–induced Active Fatal Anaphylaxis in 
W/W
 
v
 
 Mice
 
Mice Mortality
 
no. of dead/total
 
1
 
/
 
1
 
9/9
 
W/W
 
v
 
14/14
Mice were sensitized by intraperitoneal injection of 500 
 
m
 
g of Pen
V–OVA plus 2 3 109 B. pertussis and 1.0 mg of alum. Challenge was
given as an injection of 100 mg i.v. of Pen V–BSA 14 d later.1589 Choi et al.
and excitability, for the first 20–30 s after the challenge,
then ruffling of fur, dyspnea, sluggish gait, paresis, prostra-
tion, and convulsion, followed by death were observed.
Mast cell–deficient W/Wv mice exhibited the same 100%
(14/14) death rate as control mice. However, the shock
signs and death were somewhat delayed, for z4–5 min, in
W/Wv mice.
Anti–IL-4 mAb Prevents Pen V–induced Fatal Anaphylaxis in
W/Wv Mice. To confirm that the fatal reactions in W/Wv
mice are IgE-dependent, we examined whether anti–IL-4
mAb, which is effective to suppress IgE but not IgG produc-
tion (12, 14), could prevent Pen V–induced fatal anaphylaxis
in W/Wv mice. Administration of 1 mg of anti–IL-4 on days
0 (30 min before sensitization), 2, and 4 completely pre-
vented the fatal reactions, but the control anti-NP mAb did
not show any protective effect (Table 2). Blood samples
were taken 1 h before challenge from the mice, and serum
levels of IgE and IgG were determined by PCA and
ELISA, respectively. Anti–IL-4 mAb significantly sup-
pressed (by .90%) the Pen V–specific IgE responses, but
did not suppress the IgG1 response. The IgE response was
not suppressed in mice treated with anti-NP mAb. These
findings confirmed our previous observation (12) that IgE
Abs play a major role in Pen V–induced active anaphylaxis.
Taken together, these data indicated that IgE-dependent
anaphylaxis did occur in mast cell–deficient mice.
PAF Is Critical for the Fatal Reactions in W/Wv Mice.
PAF is thought to be critical for murine fatal anaphylaxis, as
PAF antagonist can prevent death (18–20). Pretreatment
with the PAF antagonist BN 50739 (200 mg/mouse) 10
min before challenge injections completely blocked the fa-
tal reactions in both 1/1 and W/Wv mice (Table 3), indi-
cating that PAF is critical for the fatal reaction in both
strains of mice. To confirm the association of PAF with fa-
tal reactions in W/Wv mice, levels of plasma PAF, together
with histamine levels, were determined. As shown in Fig. 1
a, PAF was released immediately upon challenge injection
and reached a peak in the circulation within 2 min in 1/1
mice. In contrast, a significant level of PAF was not de-
tected by 3–4 min in W/Wv mice, but it increased thereaf-
ter to a peak level that was 70–80% that of control mice, at
6–7 min. The postchallenge plasma histamine levels in 1/1
mice were similar to PAF, but histamine levels barely in-
creased in W/Wv mice (Fig. 1 b).
Discussion
Jacoby et al. (4) and Ha and colleagues (5, 6) reported
that fatal anaphylaxis can occur in mast cell–deficient mice
upon challenge with specific antigens. Some physiological
responses, such as hypotension and cardiopulmonary alter-
ation associated with anti-IgE– and specific antigen–
induced active anaphylaxis (7, 8), developed to a similar
degree in both normal and mast cell–deficient mice. How-
ever, these data are from studies using protein antigens such
Table 2. Anti–IL-4 mAb Prevents Pen V–induced Active Fatal 
Anaphylaxis in W/Wv Mice
Ig level‡
Mice Anti–IL-4* Mortality IgE IgG1
no. of dead/total PCA titer mg/ml
1/12 8/8 70 6 22 2.5 6 0.4
1/11 0/8 ,4§ 2.4 6 0.6
1/1 Anti-NP 7/7 64 6 12 1.9 6 0.2
W/Wv 2 8/8 64 6 16 2.3 6 0.4
W/Wv 1 0/10 ,4§ 1.9 6 0.4
W/Wv Anti-NP 6/7 60 6 12 2.0 6 0.3
*1 mg i.p. of mAbs was injected on days 0 (30 min before sensitization),
2, and 4.
‡Mice were partially bled 1 h before challenge, and serum levels of Pen
V–specific IgE and IgG1 were determined by a PCA reaction and
ELISA, respectively. The results are expressed as mean 6 SEM.
§Statistical differences analyzed by Student’s t test were considered sig-
nificant at P , 0.05 compared with saline-injected control.
Table 3. PAF Antagonist Prevents Pen V–induced Active Fatal 
Anaphylaxis in W/Wv Mice
Mice BN 50739* Mortality
no. of dead/total
1/12 6/6
1/11 0/6‡
W/Wv 2 6/6
W/Wv 1 0/6‡
*BN 50739 (200 mg i.p.) was injected 10 min before challenge.
‡Statistical differences analyzed by Student’s t test were considered sig-
nificant at P , 0.05 compared with saline-injected control.
Figure 1. Postchallenge plasma PAF and histamine levels in 1/1 (filled
circles) and W/Wv (open circles) mice. After challenge, blood was taken from
the heart, which was cut open at the time indicated, and was mixed with
a 0.1 vol of 3.8% ice-chilled citrate solution, then centrifuged immedi-
ately. Plasma PAF and histamine levels were determined as described in
Materials and Methods. The results were expressed as mean 6 SEM from
one of two representative experiments (n 5 2–4 animals for each time
point), and statistical significance was determined by the Mann-Whitney
U test (*P , 0.05; ‡P , 0.01 compared with 1/1 mice).1590 Role of Mast Cells in IgE-dependent Anaphylaxis
as OVA, BSA, or CGG. In protein-induced anaphylaxis, IgE
Abs are not absolutely required, since (a) fatal anaphylaxis
occurs in IgE-deficient mice (11), and (b) antigen-specific
polyclonal and monoclonal IgG Abs are capable of induc-
ing a fatal reaction in normal as well as mast cell–deficient
mice (9, 10). The implications of IgG Abs in human fatal
anaphylaxis (21) clearly indicate that IgG, in addition to
IgE, Abs are critical for protein-induced fatal anaphylaxis.
Furthermore, recent works have demonstrated that ana-
phylactic reactions can be induced in normal or mast cell–
deficient mice that have received passive transfer of anti-
gen-specific IgG1 Abs, and that these reactions reflect the
binding of these Abs to FcgRIII, which can be expressed
on the surface of mast cells as well as other cell types in the
mouse (22, 23). Thus, it is likely that, in addition to mast
cells, other cells which bind to IgG Abs, such as macrophages,
platelets, and eosinophils (24), represent the source of the
mediators in protein-induced fatal anaphylaxis. However,
the role of mast cells in an exclusively IgE-dependent
anaphylaxis has never been convincingly demonstrated be-
cause of the lack of a suitable experimental animal model.
The recent development of a murine model of IgE-depen-
dent anaphylaxis induced by the hapten Pen V (12) has
made it possible to investigate the role of mast cells in IgE-
dependent anaphylaxis.
In this study, we have shown that genetically mast cell–
deficient W/Wv mice expressed active fatal reactions to Pen
V that were indistinguishable from those in control 1/1
mice in terms of death rate. Consistent with our previous
report (12), 100% (9/9) of congenic normal 1/1 mice
died of shock upon challenge injections. The same mortal-
ity was elicited in mast cell–deficient W/Wv mice, although
signs of shock and death were delayed by 5 min. Adminis-
tration of anti–IL-4 mAb, as low as 3 mg from the day of
sensitization, completely prevented fatality and suppressed
(by .90%) Pen V–specific serum IgE, but not IgG, re-
sponses. Despite the presence of 2–3 mg/ml of Pen V–spe-
cific circulating IgG1 Abs, anti–IL-4–treated mice did not
show any signs of shock, suggesting that IgG1 Abs do not
contribute importantly to Pen V–induced fatal anaphylaxis.
In contrast to these findings, IgG1-dependent active or pas-
sive anaphylaxis can be elicited in W/Wv mice (10, 22).
These differences may be attributed to the different types of
IgG1 Abs, i.e., Ab against protein or hapten. This hypothe-
sis was further strengthened by our unpublished observa-
tions that induction of passive anaphylaxis by administra-
tion of 2 mg of anti–Pen V IgG1 (12) mAb resulted in
eliciting only mild shock signs, such as itching, whereas the
same concentration of anti-CGG IgG1 mAb (9) induced
40% fatal reactions in C57BL/6 mice. Taken together, our
data confirmed our previous results (12) that IgE Abs were
found to play a major role in Pen V–induced fatal anaphy-
laxis, and indicate that IgE-dependent anaphylaxis occurred
in mast cell–deficient mice. In this study, we have also ex-
amined whether passive transfer of IgE from immunized
normal mice can transfer anaphylactic reactivity to naive
mast cell–deficient mice. Both 1/1 and W/Wv mice were
intraperitoneally injected three times at 10-min intervals
with 0.4 ml of sera taken from Pen V–sensitized C57BL/6
mice and were challenged 24 h later (12). Upon the chal-
lenge injections, four out of four 1/1 mice developed se-
vere anaphylactic signs, such as prostration and paresis,
whereas six out of six W/Wv mice showed only mild signs,
such as itching and slight limitation of movement (data not
shown). Although a weaker passive anaphylactic reaction
occurred in W/Wv mice, these findings further support our
conclusion that mast cell–deficient mice can express IgE-
dependent anaphylactic reactions.
PAF is produced by a variety of cells involved in inflam-
matory reactions, including neutrophils, basophils, mast
cells, monocytes/macrophages, platelets, and endothelial
cells (25, 26). Recent studies have demonstrated that a PAF
antagonist prevents murine fatal anaphylaxis (18–20), indi-
cating that PAF is critical for murine fatal anaphylaxis. Pre-
treatment with the PAF antagonist BN 50739 10 min be-
fore challenge completely blocked the Pen V–induced fatal
anaphylaxis in both 1/1 and W/Wv mice. BN 50739 also
completely blocked other signs of shock in both strains of
mice, suggesting that PAF is critical for IgE-dependent
anaphylaxis even in mast cell–deficient mice. The PAF an-
tagonist BN 50739 is a synthetic PAF analogue counteract-
ing the effects of endogenous PAF by inhibiting PAF bind-
ing to its receptor and the subsequent cellular responses.
We have proved the efficacy of this reagent as a PAF
blocker in other studies (27, 28). Our time–kinetic study
revealed that the initial rapid increase in plasma PAF level
and the peak PAF levels were delayed by 4–5 min in W/Wv
mice compared with 1/1 mice. This finding suggests that
mast cells represent the source of PAF released immediately
upon challenge in 1/1 mice, and may explain the 5-min
delay of shock signs and death in W/Wv mice. The peak
level of plasma PAF in W/Wv mice was 70–80% that of
control mice. In contrast, little histamine was detected in
W/Wv mice, confirming that histamine is a major vasoac-
tive mediator released by activated mast cells (29, 30).
Taken together, these data indicate that cells other than
mast cells are enough to elaborate a sufficient amount of
PAF to cause death.
It was not clear which cell populations represent the
source of PAF in the W/Wv mice in this study. As Pen
V–induced anaphylaxis is an IgE-dependent reaction, the
cells which express IgE receptors on their surfaces would
be involved in the reaction. In humans, the FceRI is ex-
pressed on mast cells, basophils, Langerhans cells, eosino-
phils, some monocytes, and platelets (31–35). So far, how-
ever, there is no evidence that FceRI can be expressed on
cells other than mast cells and basophils in the mouse (36).
Furthermore, it has been reported that FceRI is more
widely distributed on hematopoietic cells than had previ-
ously been suspected (37). Given these considerations, the
main candidate for a source of PAF in IgE-dependent ana-
phylaxis in W/Wv mice would appear to be basophils.
In summary, these results show that IgE-dependent fatal
anaphylaxis can be elicited in mast cell–deficient mice, indi-
cating that mast cells are not essential for the development
of IgE-dependent immediate hypersensitivity reactions.1591 Choi et al.
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